Hostname: page-component-77c89778f8-swr86 Total loading time: 0 Render date: 2024-07-17T09:09:00.407Z Has data issue: false hasContentIssue false

P03-346 Effects of Placebo-Controlled Withdrawal After Long-Term Open Label Treatment with OROS MPH in Adults with ADHD

Published online by Cambridge University Press:  17 April 2020

S. Kooij
Affiliation:
Psycho Medical Centre, Parnassia, Den Haag, The Netherlands
H.J. Nyrerod
Affiliation:
Drammen Psykiatriske Senter, Sykehuset Buskerrud HF, Drammen, Norway
M. Casas
Affiliation:
Psychiatry, C/Emancipacio, Barcelona, Spain
J. Dejonckheere
Affiliation:
SGS Life Sciences Services, Antwerpen, Belgium
S. Waechter
Affiliation:
EMEA Medical Affairs, Janssen Cilag Switzerland, Baar, Switzerland
J. van Oene
Affiliation:
EMEA Medical Affairs, Janssen Pharmaceutica, Tilburg, The Netherlands
B. Schaeuble
Affiliation:
EMEA Medical Affairs, Janssen Cilag GmbH, Neuss, Germany
J. Buitelaar
Affiliation:
Psychiatry, UMC St. Radbout, Nijmegen, The Netherlands

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

To explore maintenance of effect with OROS MPH in adults with ADHD.

Methods

Multicenter study randomizing adult subjects with ADHD who completed open-label (OL) treatment with OROS MPH (18-90mg/day) for at least 52-week and consented to a 4-week, randomized, double-blind (DB), placebo-controlled (PLC) withdrawal period. Efficacy measures included total CAARS score, CAARS-S:S, GAE, CGI-S and CGI-C. Endpoint analyses were performed using LOCF.

Results

99/155 patients completed the OL OROS MPH treatment phase, only 45/99 patients consented to double-blind randomization. At DB baseline, mean ± SD TCS was 12.1±5.34 (n=23) in the continued OROS MPH group and 16.5±7.49 (n=22) in the placebo group. CAARS changed from DB baseline to DB endpoint by 4.0±7.61 and 6.5±7.82, respectively (p = 0.2586 between groups). CGI-C scores indicated more worsening of symptoms in the placebo group compared to the continued PR OROS MPH (p = 0.0422). Median (range) GAE scores at endpoint were 2.0 (0-3) and 0.5 (0-3), respectively (p=0.0254). Other efficacy endpoints were numerically in favor of OROS MPH. The randomized withdrawal phase may have been underpowered to show statistical significance between treatment groups for the primary outcome. The incidence of treatment-emergent AEs during the DB phase was comparable between groups.

Conclusions

The results indicate that treatment discontinuation after long-term exposure of adults with ADHD to OROS MPH is associated with worsening of clinical symptoms. Statistical significance for several outcomes was not reached, possibly due to study limitations.

Type
Psychopharmacological treatment and biological therapies
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.